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ed.2012.Abstract Spasticity is a wide spectrum disease that affects all age groups. Spasticity in children
may have diverse etiologies; this article will focus on children with spasticity, most of whom have
diagnoses of cerebral palsy; as approximately two thirds of all cerebral palsy patients suffer from
spasticity. This review is meant to discuss various aspects of spasticity; nomenclature over succes-
sive decades, clinical manifestations; including clinical examination tips, etiology, pathogenesis and
pathophysiology were also high lightened. We are discussing well established, as well as other recent
measures of management spasticity in view of diagnostic, as well as therapeutic approaches; includ-
ing two clinical vignettes.
ª 2012 Taibah University. Production and hosting by Elsevier Ltd. All rights reserved.Introduction
Spasticity may result from either diffuse or localized pathology
of the cerebral cortex, brain stem, or spinal cord; Cerebral
palsy is considered a main cause of spasticity in pediatric age
group as 2/3 of all cerebral palsy patients suffer from spastic-
ity. Management of spasticity is challenging as it is important
to evaluate the advantages and disadvantages that the patients
gain from their spasticity so that treatment strategies and goals
can be identiﬁed. Prenatal care during pregnancy can avoid
premature labor; prevent cerebral palsy in infants with its
resulting spasticity. Despite major updates and innovationsnt of Pediatric Neurology,
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12.004in the ﬁeld of treatment of spasticity, there is no speciﬁc diag-
nostic test for spasticity.
Historical note and nomenclature
Treatment for spasticity was documented as early as the late
19th century, when surgeons Abbe and Bennet discussed the
decreasing tone in a spastic limb through sensory rhizotomies.
Later, in 1898, the scientist Sherrington published experiments
in which the sensory roots of spastic cats were severed to re-
lieve spasticity. 2 The technique of sensory rhizotomies has
been improved on and continues to be used today as a treat-
ment for patients with spasticity as does neuromuscular block-
age, a longstanding treatment, which has been used for over
30 years.36
Clinical manifestations
Spasticity was deﬁned by Lance as a ‘‘velocity-dependent in-
crease in tonic stretch reﬂexes (muscle tone) with exaggerated
tendon jerks, resulting from hyperexcitability of the stretch re-
ﬂex’’.57,25 Young further added characteristics of positive and
negative symptoms. Positive symptoms consist of exaggeratedLtd. All rights reserved.
54 Y. Awaad and T. Rizkcutaneous reﬂexes, including nociceptive and ﬂexor with-
drawal reﬂexes, autonomic hyperreﬂexia, dystonia, and con-
tractures. Negative symptoms include paresis, lack of
dexterity, and fatigability.57
Although there are many possible causes of spasticity, this
article will focus on children with spasticity, most of whom
have diagnoses of cerebral palsy; approximately two thirds
of all cerebral palsy patients suffer from spasticity.5 A patient
with spastic cerebral palsy presents with muscle imbalance,
stands with bent knees and legs tightly together, and in severe
cases, a scissors-type gait.26,3 The antigravity muscles are
predominantly affected with arms in a ﬂexed and pronated
position and legs in an extended and adducted position. When
the muscles are at rest they are ﬂaccid to palpation and electro-
myographically silent.
Examination should begin with the patient in a relaxed,
lying position with the head up and arms resting to the sides
because it is easier to determine the extent of spasticity in this
position. The examination should include tonic stretch reﬂexes
by manual passive stretches, elicitation of tendon jerks and clo-
nus in a relaxed position, and tonic and phasic stretch reﬂexes
carried out in a sitting position.
The manual passive stretch maneuver is used to assess resis-
tance at different rates. A joint is passively moved while the
muscles corresponding to that joint are lengthened and short-
ened. In cases of mild spasticity, the muscles will only resist
when stretched at a high rate, whereas in cases of moderate
spasticity, resistance is noticed at a slower rate and the clasp-
knife phenomenon may be exhibited. Movement of the muscle
may be difﬁcult to impossible in cases of severe spasticity.19
The muscle tone is graded according to the Ashworth scale,
a scale ranging from 1 to 5, in which resistance to the passive
muscle stretch is measured at various velocities.5
Tendon jerks are easier to elicit in spastic patients than in
patients with normal muscle tone, and reﬂex responses can
be achieved in muscles without well-deﬁned tendons. Percus-
sion of the tendon reveals hyperactive tendon jerks, especially
for the Achilles, patellar, biceps, and triceps tendons.58 On
EMG, the jerks show greater amplitudes than are normal
and are followed by after-discharge of the motor units that is
often slightly longer lasting than normal. The size of tendon
jerks can be measured by either EMG response or by record-
ings of mechanical events.
H-reﬂex (Hoffmann’s reﬂex) studies are electrically elicited
tendon jerks and are restricted mostly to the soleus and ﬂexor
carpi radialis muscles in normal adults. In cases of upper mo-
tor neuron lesions, the H-reﬂex may be elicited in muscles
where it is not normally seen, such as the intrinsic hand mus-
cles, tibialis anterior, or peroneal muscles.58
Measurement of resistance to passive stretch, reduction in
the tonic vibration reﬂex, and reduction of the plantar
withdrawal reﬂex should also be evaluated.Motoneuronal over-
activity should also be evaluated because any input tomotoneu-
rons produces excessive and prolonged activity that can be
observed in the contractions of many limb muscles.58
The amount of function the patient derives from spasticity
can be evaluated by having the patient obtain and maintain
standing and seated positions. To determine the degree to which
the hamstring tone is affecting the alignment of the pelvis and
knees, have the child sit with feet straight in front. The patient
can sit in a chair to allow the examiner to assess trunk control.
The side sit position exhibits a patient’s ability to maintain con-trol in an asymmetric position.1 Video cameras are often helpful
during evaluation as the patient’s movements can be recorded
and compared against movements during and after treatment.
It is important to evaluate the advantages and disadvan-
tages that the patient gains from their spasticity so that treat-
ment strategies and goals can be identiﬁed. Disadvantages may
include interference with activities of daily living, inhibition of
good sleep, contractures, dislocations, skin breakdown, bowl
and bladder dysfunction, impairment of respiratory function,
pain with stretching, and the masking of the return of volun-
tary movement. However, patients may rely on a certain
amount of spasticity to function and the advantages they
may receive include maintaining muscle tone, supporting circu-
latory function, assisting in activities of daily living, and pre-
venting the formation of deep vein thrombosis.Clinical vignette
Patient A was a 5-year-old African–American boy with a his-
tory of developmental delay and a diagnosis of cerebral palsy
of the spastic-diplegic type. He ﬁrst presented at 18 months
with severe spasticity in both lower extremities. The patient
walked on tip toes and had hip and knee ﬂexion. There was
some scissoring of the legs. On examination, exaggerated deep
tendon reﬂexes were elicited, as were sustained clonus and
bilateral Babinski sign. MRI of the brain showed ﬁndings that
may be secondary to previous hypoxic injury, compatible with
cerebral palsy. Prior treatments included physical therapy,
bilateral ankle-foot orthosis, serial casting, and oral baclofen.
Before treatment with botulinum toxin injections, the patient
was a tip-toe walker. With treatment the patient’s gait has im-
proved; he is ﬂat-footed and presently wears bilateral ankle-
foot orthosis. His hygiene and positioning have also improved
and he returns every 6 months to 9 months for reinjection.
Patient B was a 7-year-old African–American boy with a
history of cerebral palsy of the spastic-diplegic type. On pri-
mary examination he presented with tightness of both ham-
strings and heel cords with the right more involved than the
left. The patient had good toe standing, especially on the right
side and good sitting balance with a kyphotic sacral-type sitting
due to the tight hamstring. He uses a walker to ambulate and
walks on tip toes. The EEG was abnormal, indicating the pres-
ence of epileptiform activity from the left central parietal head
region and diffuse background disorganization, which indi-
cates underlying neuronal dysfunction. Treatments before
intrathecal baclofen pump implantation included bilateral an-
kle-foot orthoses, tendon releases, alcohol block, and botu-
linum toxin injections. Before treatment with intrathecal
baclofen the patient was dependent on a care giver and used
a walker to ambulate. With the intrathecal baclofen pump
the patient has gained function, does not use a walker to ambu-
late, and performs activities of daily living independently.Etiology
Spasticity may result from either diffuse or localized pathology
of the cerebral cortex, brain stem, or spinal cord. Possible
causes of such injuries include cerebral palsy, traumatic brain
injury, stroke, multiple sclerosis, spinal cord trauma, or disease
and anoxic insults. The neurologic localization of the lesion
causing spasticity may result in different clinical manifesta-
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results from cerebral pathology, whether it is diffuse or local-
ized, or whether it is a result of spinal cord injury. Diffuse cere-
bral injury or diseases would include anoxia, toxic, or
metabolic encephalopathies, whereas localized cerebral injury
would include tumor, abscess, cyst, arteriovenous malforma-
tions, hemorrhage, or trauma. Spinal cord injury or disease
may result as an insult to descending pathways by trauma,
inﬂammatory or demyelinating disease, degenerative disorders,
or compression such as is caused by a tumor or cyst.19,26,5
Common causes of cerebral palsy in children that may result
in spasticity are prolonged second stage labor, fetal distress,
cystic degeneration of the brain, prematurity, periventricular
encephalomalacia, cortical abnormalities such as porenceph-
aly, or congenital malformations of gyri such as micropolygy-
ria. The annual incidence of spinal cord injuries in the United
States is estimated to be 30–40 new cases per million individu-
als. About 3–5% of cases each year occur in children younger
than 15 years of age.45 The male-to-female ratio of patients is
4:1 in the general population, but in younger age groups, the
ration is approximately 1.5:1.59
Pathogenesis and pathophysiology
There are many different types of spasticity. Because of this,
more than one mechanism may be responsible for the distur-
bance in muscle tone and the mechanisms may vary between
patients. The neuropathophysiologic processes involved in
spasticity are complex and not fully understood, but there is
a widely accepted hypothesis that spasticity depends on hyper-
excitability of spinal alpha motor neurons, which is due to the
interruption of descending modulatory inﬂuences carried by
the corticospinal, vestibulospinal, and reticulospinal tracts
and other possible tracts.24 Ia afferent ﬁbers provide segmental
input from muscle spindles to alpha motor neuron pools. They
synapse on segmental inhibitory interneurons that then inhibit
alpha motor neurons innervating antagonist muscles in the Ia
reciprocal inhibition pathway. Ib afferents inhibit alpha motor
neurons by way of the Golgi tendon organs via the Ib inhibi-
tory interneuron in another pathway known as nonreciprocal
inhibition.57,24 Increased excitation of these afferents does
not seem to be the cause of spasticity. Instead, evidence sup-
ports that reduced reciprocal inhibition of antagonist motor
neuron pools by Ia afferents, decreased presynaptic inhibition
of Ia afferents, and decreased nonreciprocal inhibition by Ib
terminals are all possible pathophysiologic mechanisms of
spasticity.57 The pathophysiology of traumatic brain injury in-
volves a complex combination of forces that has been a subject
of substantial debate.21 On occasion, autonomic dysreﬂexia
may occur after an intramuscular injection, although this is rel-
atively rare.49 In some patients, autonomic dysreﬂexia may oc-
cur even if the level of spinal injury is below T6.7,37 The use of
antihypertensive pharmacologic agents in treating spasticity is
unclear because randomized trials have not been performed.
Nifedipine has been used in a bit-and-swallow technique; more
recently, captopril also has been found to be of beneﬁt.22
Epidemiology
As stated before, spasticity is present in about two thirds of
cerebral palsy patients, and cerebral palsy affects anywherefrom 1.5 to 2.5 per 1000 live births in the United States.3
The number of spastic patients continues to increase due to
an increased survival rate of premature births. Males and fe-
males are equally affected.
Prevention
To prevent cerebral palsy; due to preterm labour; and, thus,
the resulting spasticity, it is important that mothers receive
prenatal care during pregnancy, that measures are taken to
avoid premature labor, and that special consideration is given
to pregnancies involving multiple gestations. Early detection
and treatment of other causes of cerebral palsy, e.g. neurode-
generative diseases may prevent the development of spasticity
as well as detect the underlying diseases that could result in
brain injury. If children have conditions that make them sus-
ceptible to brain or spinal cord injury or both, safety measures
should be taken (i.e., helmets for patients who have frequent
seizures).
Differential diagnosis
Spasticity can be confused with rigidity when a patient is being
evaluated. Stretching can distinguish rigidity from spasticity.
Rigidity will relax through repeated stretching of a muscle,
whereas a spastic muscle will continue to increase in resistance
as the velocity of the stretch is increased.19,57
Diagnostic workup
There is no speciﬁc diagnostic test for spasticity. Testing can be
done to establish the presence of any lesions or brain or spinal
cord injury. MRI of the brain can be performed to rule out
periventricular leukomalacia. A baseline EEG to establish
underlying seizure activity can also be done as well as basic
lab studies. Neurophysiological studies, such as the H-reﬂex
study, may be performed in patients with neurodegenerative
disease; an enzymatic assay should also be performed.
Prognosis and complications
Spasticity results in limited functional capacity and increased
inactivity. The sequelae of this inactivity may include decubiti,
cardiovascular problems, thrombophlebitis, respiratory infec-
tions, ﬁxed contractures, osteoporosis,33 bladder and bowel
problems, and social isolation. Ultimately, these consequences
of inactivity may lead to a further decrease in strength and
function.25 The patient’s quality of life may be compromised
as spasticity has negative impacts on mobility, hygiene, self
care, sleeping patterns, self esteem, mood, and sexual function.
Management
Traditional treatments for spasticity include physical and occu-
pational therapy, in which the patient is stretched anywhere
from once daily to several times per day, but this has only a lim-
ited effect on the patient’s spasticity. Rehabilitation treatment
options include casting, orthotics or splints, strengthening,
electrical stimulation, practice of functional tasks, sensory inte-
gration; muscle stretching, and targeted muscle training.23
Within the scope of pediatric neurorehabilitation, distinct
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tions; however, can also occur in association with many disor-
ders. For example, spasticity from injury to the upper motor
neuron unit can develop in many neurologic disorders in chil-
dren. Several of these complications, such as autonomic dysref-
lexia, deep vein thrombosis, and heterotropic ossiﬁcation, can
be severe and potentially life-threatening.20,18
Oral medications can be used to decrease spasticity; how-
ever, many have unwanted side effects such as drowsiness, seda-
tion, confusion, and fatigue. Benzodiazepines, such as
diazepam, are rarely used because of their strong sedating ef-
fects. They result in enhanced presynaptic inhibition, but be-
cause they are presumed to enhance the postsynaptic effects
of GABA, they can only work if the GABA-mediated process
functions. Benzodiazepines have a long half-life and an active
metabolite. Benzodiazepine therapy is indicated in spinal cord
injury and multiple sclerosis with possible application in trau-
matic brain injury, cerebral palsy, and cerebrovascular acci-
dent. Clinical effects include sedation and reduced anxiety,
decreased resistance to passive range of motion, decreased
hyperreﬂexia, and reduction in painful spasms. Side effects of
all benzodiazepines include sedation, weakness, hypotension,
gastrointestinal symptoms, memory impairment, incoordina-
tion, confusion, depression, and ataxia. Also, benzodiazepines
are controlled substances with the potential for dependency.
Diazepam is the most widely used benzodiazepine for spasticity
management. The recommended initial dose is 250 mcg/kg
three times daily with a maximum dose of 60 mg daily (20 mg
three times daily). If nocturnal spasticity is the presenting prob-
lem the patient should be started with a single dose at night.
Like benzodiazepines, baclofen works centrally. Baclofen
binds with GABA-B receptors on brain and spinal membranes,
restricting calcium inﬂux into presynaptic nerve terminals,
thereby reducing spasticity.25 The use of baclofen is indicated
when spasticity is of spinal origin. The clinical effects include
decreased resistance to passive range of motion, decrease in
hyperreﬂexia, and reduction in painful spasms and clonus.
Unlike benzodiazepines and baclofen, dantrolene sodium
works peripherally at the level of the muscle ﬁber. It has no ef-
fect on neuromuscular transmission, but works by acting di-
rectly on the skeletal muscle, hindering the release of calcium
from the sarcoplasmic reticulum, thereby preventing the exci-
tation-contraction coupling mechanism. This affects both
intrafusal and extrafusal ﬁbers by decreasing the force of mus-
cle contraction. However, this mechanism is not selective for
muscles with increased tone, and the resulting generalized mus-
cle weakness may weaken respiratory muscles. The use of dan-
trolene sodium is indicated in treating spasticity secondary to
cerebrovascular accident, cerebral palsy, and has possible
applications for traumatic brain injury, spinal cord injury,
and multiple sclerosis. Clinical effects of dantrolene sodium in-
clude decreased resistance to passive range of motion, decrease
in hyperreﬂexia and tone, and reduction in spasms and clonus.
Another group of oral medications used in spasticity man-
agement includes clonidine and tizanidine, which are alpha2,
nonadrenergic receptor agonists that release excitatory neuro-
transmitters and inhibit supraspinal facilitatory pathways.57,25
Tizanidine is an oral antispasticity agent that is selective in
decreasing tone and spasm frequency in only spastic muscles,
eliminating the unwanted side effect of generalized muscle
weakness. Tizanidine is reported to have reduced symptoms
of spasticity in patients with multiple sclerosis or spinal cordinjury and is well tolerated in most patients. It is an imidazo-
line derivative similar to clonidine but without the cardiovas-
cular effects when appropriately titrated. Tizanidine results
in a direct reduction of excitatory amino acid release from
spinal interneurons and inhibits facilitatory caerulospinal
pathways. Its peak effect occurs 1–2 h following administra-
tion and its half-life is 2.5 h. The clinical effects of tizanidine
include reduced muscle tone, spasm frequency, and hyperre-
ﬂexia. Animal studies with tizanidine demonstrate antinocicep-
tive activity under speciﬁc conditions with increased dose
titration.17,14,55,39 As with other antispasticity medications,
the potential side effects of tizanidine are dose related and
may be mitigated by dosage titration. The potential side effects
include drowsiness, dry mouth, and dizziness. Literature sug-
gests that tizanidine may be better tolerated than other anti-
spasticity agents as measured by the global tolerance rating
scale.38 In placebo-controlled studies, tizanidine has been
shown to be effective in multiple sclerosis and spinal cord in-
jury. It is also useful for spasticity of spinal pathology when
weakness is of concern. Tizanidine may also prove effective
in managing spasticity of cerebral origin.40
Secondary oral and systemic agents include tiagabine,
cyproheptadine, clonidine, lamotrigine, gabapentin and carbi-
dopa-levodopa.27 Multiple medications have been recom-
mended, of which the most recent addition is gabapentin.59
Other treatments include chemical neurolysis, in which the
nerve conduction is impaired through the use of chemical
agents and therapeutic nerve block using phenol or alcohol.
The goals of these treatments are to prevent muscle contrac-
tures and improve the patient’s function. A common side effect
is that after the nerve is injected, alcohol levels measure above
the legal limit in children. Other side effects include damage to
sensory and motor nerves, pain at injection site, scarring, and
dysesthesias. To ensure the correct site, injection must be made
using an electrical stimulator.57,25
Another treatment used alleviate spasticity in children with
cerebral palsy is rhizotomy. Studies have shown that perform-
ing selective dorsal rhizotomy at a young age can reduce the
need for orthopedic surgery.11 Goals of rhizotomy are de-
creased tone, increased mobility, and the facilitation of care
for the patient, however, the reduction in spasticity cannot
be predicted and sometimes results in excessive hypotonia.29
The procedure is very meticulous, requiring general anesthesia
and a neurophysiologist who must be present to identify which
nerve is to be severed.
Other neurosurgical approaches include peripheral neurec-
tomy, myelotomy, and dorsal column electrical stimulation.
Orthopedic procedures are the most frequently performed
operations for spasticity. The targets of these operations are
muscles, tendons, or bones. Muscles may be denervated and
tendons and muscles may be released, lengthened, or trans-
ferred. The goals of surgery may include reducing spasticity,
increasing range of motion, improving access for hygiene,
improving the ability to tolerate braces, or reducing pain.
Orthopedic problems that may result from a spastic limb in-
clude cubital or carpal tunnel syndrome, spontaneous fracture,
gait difﬁculties, dislocation of the hip or knee, and heterotopic
ossiﬁcation.
The most common orthopedic procedure for the treatment
of spasticity is a contracture release. In this procedure, the
tendon of a muscle that has a contracture is partially cut,
completely cut or lengthened. The joint is then positioned at
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tendon to a new length occurs over several weeks. Serial cast-
ing may be used to gradually extend the joint. Following cast
removal, physical therapy is used to strengthen the muscles
and improve range of motion.
Spastic muscles in the shoulder, elbow, forearm, hands, and
legs may all be treated with tendon or muscle lengthening.
Spasticity in the shoulder muscles may cause abduction or
adduction and internal rotation of the shoulder. Abduction re-
sults in difﬁculties with balance, which then affects walking
and transferring, and adduction causes problems when reach-
ing for an object or with hygiene and personal care. An oper-
ation known as a slide procedure may be used to lengthen the
supraspinatus muscle in an abducted spastic shoulder. With
adducted shoulders, the surgeon can perform a release of all
four muscles that typically cause this deformity.
In an operation known as a tendon transfer, the orthopedic
surgeon moves a tendon from the spot at which it attaches to
the spastic muscle. With the tendon transferred to a different
site, the muscle can no longer pull the joint into a deformed
position. In some situations, the transfer allows improved
function. In others, the joint retains passive but not active
function. Ankle-balancing procedures are among the most
effective interventions.
Osteotomy and arthrodesis involves operations on the bones
and are usually accompanied by operations to lengthen or split
tendons to allow for fuller correction of the joint deformity.
Osteotomy can be used to correct a deformity that cannot be
ﬁxed with other procedures. In an osteotomy, a small wedge
is removed from a bone to allow it to be repositioned or re-
shaped. A cast is applied while the bone heals in a more natural
position. Osteotomy procedures are most commonly used to
correct hip displacements and foot deformities. Arthrodesis is
a fusing together of bones that normally move independently.
This fusion limits the ability of a spastic muscle to pull the joint
into an abnormal position. Arthrodesis procedures are per-
formed most often on the bones in the ankle and foot. In triple
arthrodesis, the three joints of the foot are exposed (talocalca-
neal (TC), talonavicular (TN), and calcaneocuboid (CC)
joints), the cartilage is removed, and screws are inserted into
the bones, ﬁxing the joints into position. With a short walking
cast in place for 6 weeks or until the bones have fully healed, the
patient may bear weight immediately after the operation.56 The
risks of developing a structural spinal deformity ranges from
24% to 36% for scoliosis and is 50% for lordosis for an average
of 4–11 years after selective dorsal rhizotomy.54,30
Other principals include single event, multilevel surgery;
surgery is delayed as long as possible (more than 6 years).
Spasticity management is used as an adjunct to surgical inter-
vention.9Alternative medicine in spasticity management
Physical modalities include electrical stimulation and cold
temperature,10,42,47,34 acupuncture and homeopathic
approaches.28 herbs and hyperbaric oxygen,4,35,41,44,13 con-
straint induced training,52,15 the Adeli suit,50 conductive edu-
cation, craniosacral, and manipulation and patterning.
Context therapy is a new intervention approach that
focuses on changing the task and the environment rather than
children’s impairments. It can be a viable treatment to achieveparent-identiﬁed functional goals for children with cerebral
palsy.16
New treatments for spasticity, such as botulinum toxin type
A, have proved easier, more effective, and less painful for pa-
tients. First clinically introduced in the United States in the
early 1980s, botulinum toxin is a potent neurotoxin derived
from the anaerobic bacteria Clostridium botulinum, but when
used in treatment, no serious systemic toxin effects have been
reported.25 The medication is more costly than alcohol or phe-
nol but the cost is offset by less physician time and the lack of
anesthesia. The formation of antibodies has been a concern,
but this can be prevented by allowing 2–3 months between
injections. Botulinum toxin works by acting in the neuromus-
cular junction, preventing the release of acetylcholine, which
results in functional denervation. It can be given without
EMG and anesthesia, does not cause dysesthesias, and is no
more painful than an injection of saline solution. Effects are
local and last 3–4 months, or longer. It is contraindicated dur-
ing pregnancy, lactation, in individuals with neuromuscular
disorders (such as myasthenia gravis), in patients taking ami-
noglycosides, or in those who have a known allergy to the
drug. Adverse effects are not common and are usually associ-
ated with the site of injection, such as bleeding, bruising, and
soreness or redness at the injection site, or diffusion to nearby
muscle groups. In patients that do not respond to botulinum
toxin, possible reasons should be considered before labeling
the patient as unresponsive. Reasons could be related to injec-
tion technique, improper toxin storage, or the patient’s indi-
vidual characteristics. Overall, botulinum toxin has proven
clinically to be effective, safe, and less painful than other inva-
sive therapies.25,32 Botulinum toxin is available in serotypes A
and B, which have different unit potencies, side-effect proﬁles,
and dilution schedules. Both have been used in children with
cerebral palsy, although serotype A has been used more exten-
sively. Dosing guidelines have been suggested for botulinum
toxin A for adult and pediatric patients. Adult recommenda-
tions are available for botulinum toxin B, but studies are ongo-
ing for pediatric patients.53,48,46
Several studies have reported the successful use of botu-
linum toxin A for the treatment of drooling in children with
cerebral palsy, using injection into the submandibular or par-
otid glands alone or in combination with other agents.31,8,51 In
some studies, the beneﬁcial effects have lasted for up to
4 months without serious side effects or disturbances of oral
function.31,51
It has been established that oral baclofen does not cross the
blood–brain barrier effectively and that higher doses of the
medication result in serious side effects.25 Intrathecal baclofen
results in a greater decrease in spasticity by allowing higher
concentrations of baclofen in the cerebrospinal ﬂuid at about
1% the daily oral dosage.29 To be considered for intrathecal
baclofen pump placement, the patient must have severe lower
limb spasticity that does not respond to other less-invasive
treatments. The patient must ﬁrst be given a trial of 50 lg bac-
lofen through a lumbar puncture or spinal catheter. If unre-
sponsive, 75 lg can be tried after 24 h and a third trial of
100 lg can be tried 24 h after that, after which if the patient
is still unresponsive he or she must be excluded from the treat-
ment.25 Implantation lasts 1–2 h and the pump is easy to reﬁll
subcutaneously. It is programmed by a computer-controlled
radiotelemetry programmer that is linked to the pump’s inter-
nal computer and that selects the rate and pattern of baclofen
58 Y. Awaad and T. Rizkadministration. Complications to intrathecal baclofen include
hypersensitivity to baclofen, intolerance to the side effects of
baclofen including drug tolerance, cerebrospinal ﬂuid leakage,
pump pocket seroma, hematoma, infection, and soft tissue ero-
sion. The objective of intrathecal baclofen is to individualize
the patient’s dose and infusion so that the lowest dose that
yields the greatest response can be achieved.57,25 In compari-
son, intrathecal baclofen has less complications and side effectsTable 2: Therapeutic interventions for spasticity.
Therapeutic intervention Mechanisms
Non-pharmacologic treatments
Physical and occupational therapy Stretching exercises anywhere from
several times per day
Rehabilitation program Splints, strengthening, electrical st
practice of functional tasks, sensor
muscle stretching, and targeted mu
Casting and orthosis Extend joint range diminished by
reduce an abnormal pattern by po
Selective posterior rhizotomy Balancing spinal cord-mediated fa
inhibitory control
Orthopedic surgery Corrects deformity induced by mus
involving muscles, tendons, or bon
Pharmacological treatments, oral medications
Benzodiazepine Increases the aﬃnity of GABA for
receptors; inhibitory eﬀect at both
and supraspinal levels
Dantrolene sodium Inhibits release of calcium from sa
reticulum in muscle; works periph
muscle ﬁbers
Baclofen GABA agonist; binds at the GAB
restricts calcium inﬂux into presyn
terminals in the spinal cord
Tizanidine Centrally acting alpha-2 noradrene
inhibits release of excitatory neuro
the spinal cord and supraspinally
Pharmacological treatments, chemodenervation
Alcohol/phenol block Nonselective proteolytic agents; se
denervation when injecting into m
muscles
Botulinum toxin injection High aﬃnity and speciﬁcity to the
membranes of cholinergic motor n
Pharmacological treatments, other
Intrathecal baclofen pump Using a programmable implanted
can be delivered intrathecally
Table 1: Useful tests for diagnosis.
Test Use
Basic lab studies
(electrolytes, bone proﬁle, etc.)
Metabolic derangement
Enzymatic assay
(Arylsulfatase, Neuraminadase, etc.)
Neurodegenerative disease
EEG Underlying seizure activity
NCS Neurodegenerative disease
(Leukodystrophies)
MRI of the brain Periventricular leukomalaciathan other treatments and more generalized results in both
cerebral and spinal spasticity, making intrathecal baclofen
the most effective current tool for the treatment of spasticity
in non-ambulant individuals. A recent systematic review
showed that there was no evidence to support the clinical use
of intrathecal baclofen in ambulant individuals with hyperto-
nicity without further rigorous longitudinal studies.43
As a precaution, families are prescribed diazepam or diaze-
pam rectal as well as oral baclofen to have at home. If there is
evidence of withdrawal, one of these medications is adminis-
tered, and the patient is instructed to go immediately to the
emergency department. Although aggressive use of benzodi-
azepines and oral baclofen may be helpful, recognition and re-
turn to appropriate intrathecal baclofen dosage is essential for
rapid recovery.6
The goals of and beneﬁts to the patient are important when
considering the path of treatment. In some cases, function will
not return, but treatment can result in pain reduction and al-
low easier management of patient care. Common goals are
to decrease pain, prevent or decrease contractures, improve
ambulation, facilitate activities of daily living, facilitate reha-
bilitation participation, save caregiver’s time, improve the easeMajor points
once daily to Only a limited eﬀect on the patient’s spasticity
imulation,
y integration,
scle training
Mainstays and cornerstones in spasticity
management; complications, such as autonomic
dysreﬂexia, deep vein thrombosis, and
heterotropic ossiﬁcation, can be severe and
potentially life-threatening
hypertonicity;
sitioning
Temporary eﬀect
cilitatory and Permanent eﬀect; sometimes results in excessive
hypotonia
cle overactivity
es
In moderate to severe spasticity; permanent eﬀect
GABA-A
the spinal cord
Short-term treatment; strong sedating eﬀects
rcoplasmic
erally at the
Serious side eﬀects; hepatotoxicity in 1% patients;
respiratory muscle weakness
A-B receptor;
aptic nerve
Rapidly absorbed after oral administration; levels
in the CSF are low because of low lipid solubility
rgic agonist;
transmitters in
Drowsiness, dry mouth, and dizziness; monitor
liver function
lective
otor nerves or
Damage to sensory and motor nerves; painful
dysesthesias
presynaptic
eurons
Recommended as eﬀective treatment; no sensory
disturbance
pump, baclofen Severe, generalized spasticity; less complications
and side eﬀects
Spasticity in children 59of care, and increase safety. Appropriate management choices
are based on therapeutic objectives. Physical and occupational
therapists can play a key role in identifying these objectives.
Treatments with the fewest side effects are usually given prior-
ity. Both the patient’s and the caregiver’s goals must be consid-
ered.12
A summary of therapeutic interventions is provided in
Tables 1 and 2.16. Pregnancy
The patient with spasticity may expect to have a difﬁcult preg-
nancy and delivery as well as difﬁculty managing and caring
for an infant. Close medical follow up throughout pregnancy
is recommended, hospitalization, immediate post natal care,
etc.
Anesthesia
Not applicable.References
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